

References

S-218

1. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 3.2021. Accessed May 17, 2021.
3. National Cancer Institute Physician Data Query (PDQ®). Chronic myelogenous leukemia treatment. National Cancer Institute. 2016.
4. Zhang GF, Zhou M, Bao XB, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia. *Asian Pac J Cancer Prev*. 2016; 17(9):4477-4481.
5. Gratwohl A, Pffirmann M, Zander A, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. *Leukemia*. 2016; 30(3):562-569.
6. Hayes, Inc. Comparative Effectiveness Review. *Comparative effectiveness of allogeneic hematopoietic stem cell transplant verses drug-based strategies for treatment of chronic myelogenous leukemia*. Lansdale, PA: Hayes, Inc.; Published on April 28, 2016. Reviewed on April 17, 2018. Accessed on February 18, 2020.
7. Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020;26(7):1247-1256.
8. Hayes, Inc. Hayes Comparative Effectiveness Review. *Comparative Effectiveness Review of the Influence of Stem Cell Source on Allogeneic Stem Cell Transplant Effectiveness for Treatment of Chronic Myelogenous Leukemia*. Lansdale, PA: Hayes, Inc.; June 2016.
9. Chhabra S, Ahn KW, Hu ZH, et al. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. *Blood Adv*. 2018;13;2(21):2922-2936.